Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids)
Patents for A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids) (127,169)
11/2002
11/07/2002WO2002087548A1 A pharmaceutical tablet having a high api content
11/07/2002WO2002087513A2 Fused heterocyclic inhibitors of phosphodiesterase (pde) 7
11/07/2002WO2002087511A2 Modulators of elastase inhibitor secretion
11/07/2002WO2002087508A2 Nitrosated and nitrosylated nebivolol and its metabolites, compositions and methods of use
11/07/2002WO2002087424A2 Treatment and diagnosis of macrophage mediated disease
11/07/2002WO2002067955A3 A process for the manufacture of a herbal composition comprising a matrine
11/07/2002WO2002066026A3 Tramadol-based medicament
11/07/2002WO2002047697A3 Fractions of snake blood, their preparation and use as therapeutic agents
11/07/2002WO2002045681A3 Solid polyunsaturated fatty acid compositions
11/07/2002WO2002044141A3 Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists
11/07/2002WO2002028424A3 Kyberdrug as autovaccines with immune-regulating effects
11/07/2002WO2002009768A3 Therapeutic polyesters and polyamides
11/07/2002WO2002009667A3 Dispersions for formulating slightly or poorly soluble active ingredients
11/07/2002WO2001085687A1 Substituted indoles as parp inhibitors
11/07/2002WO2001047866A9 Substituted 1 and 2 naphthol mannich bases
11/07/2002WO2001026676A9 Methods of treating or preventing cell, tissue, and organ damage using human myeloid progenitor inhibitory factor-1 (mpif-1)
11/07/2002US20020166132 System for regulating in vivo the expression of a transgene by conditional inhibition
11/07/2002US20020165399 Interphenylene 7-oxabicyclic [2.2.1] heptane oxazoles as prostaglandin F2a antagonists
11/07/2002US20020165374 Secreted protein HFEAF41
11/07/2002US20020165355 Methylated, SmD homologous peptides, reactive with the antibodies from sera of living beings affected with systemic lupus erythematosus
11/07/2002US20020165282 PPAR agonists
11/07/2002US20020165276 Method for preventing and treating inflammatory somatic pain and chronic pain
11/07/2002US20020165262 Methods and products relating to 16-HETE analogs
11/07/2002US20020165241 Such as 4-((methyl-pyrimidin-2-ylamino)-methyl)-piperidine-1-carboxylic acid benzyl ester; useful for pain relief; treating migraine, depression, anxiety, schizophrenia, Parkinson's disease, and stroke; N-methyl-D-aspartate (NMDA)
11/07/2002US20020165235 Alkoxycarbonylamino benzoic acid or alkoxycarbonylamino tetrazolyl phenyl derivatives as IP antagonists
11/07/2002US20020165211 Aqueous suspension of Fluticasone furoate; respiratory tract disorders; asthma, COPD; antiinflammatory, antiallergen; nasal inhaler
11/07/2002US20020165203 Enzyme inhibitors; antiinflammatory agents; rheumatic diseases; antidiabetic agents
11/07/2002US20020165202 Antiinflammatory agents; antiproliferative agents
11/07/2002US20020165186 Compounds that affect CD83 expression, pharmaceutical compositions comprising said compounds and methods for identifying said compounds
11/07/2002US20020165179 Multifunctional nanodevice platform
11/07/2002US20020165166 Treating thrombosis by administering a CD154 inhibitor, such as a metalloproteinase inhibitor
11/07/2002US20020165164 New effectors of dipeptidyl peptidase IV for topical use
11/07/2002US20020165156 Tumor necrosis factor family and its blocking agent
11/07/2002US20020165150 Amino acid sequence from certain regions of tissue growth factor-beta super family serine-threonine kinase receptors
11/07/2002US20020165131 Histidine-rich glycoprotein
11/07/2002US20020164789 Suppressing glial cell activation in central nervous system; obtain mammal with brain disorder, administer modulator of nervous system activity, evaluate for adjusstment in brain disorder
11/07/2002US20020164748 Enzymatic polypeptide for use in the treatment of inflammation, autoimmune and tissue rejection disorders
11/07/2002US20020164734 Human pelota homolog
11/07/2002US20020164719 Targeting pharmaceutical agents to injured tissues
11/07/2002US20020164707 Nucleotide sequences coding polypeptide for use in the treatment and diagnosis of cancer, arthrits, pain, diabetes, migraine and inflammation, hypercalcemia, obesity, hypertension, and bone defects
11/07/2002US20020164697 Nucleotide sequences coding polypeptides for use in treatment of autoimmune disease
11/07/2002US20020164692 Immune system-related polynucleotides, polypeptides, and antibodies
11/07/2002US20020164682 Mammalian cerberus-like protein and compositions
11/07/2002US20020164600 PD-L2 molecules: novel PD-1 ligands and uses therefor
11/07/2002US20020164355 Test to detect antibodies; calibration
11/07/2002US20020164331 Compositions and methods of monoclonal and polyclonal antibodies specific for T cell subpopulations
11/07/2002US20020164323 Antithrombin; antiinflammatory agents, rheumatic diseases
11/07/2002CA2594883A1 Pharmaceutically active uridine esters
11/07/2002CA2446514A1 Fused pyrimidines as antagonists of the corticotropin releasing factor (crf)
11/07/2002CA2446497A1 Crf receptor antagonists
11/07/2002CA2446079A1 Modulators of elastase inhibitor secretion
11/07/2002CA2446064A1 Nitrosated and nitrosylated nebivolol and its metabolites, compositions and methods of use
11/07/2002CA2446052A1 Compositions and methods for treating vulvovaginitis and vaginosis
11/07/2002CA2445947A1 Lipid-comprising drug delivery complexes and methods for their production
11/07/2002CA2445871A1 Combinations of aldose reductase inhibitors and cyclooxygenase-2 inhibitors
11/07/2002CA2445861A1 Pharmaceutically active uridine esters
11/07/2002CA2445839A1 Anti-inflammatory 17.beta.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.alpha
11/07/2002CA2445826A1 Treatment and diagnosis of macrophage mediated disease
11/07/2002CA2445811A1 Modified fvii in treatment of ards
11/07/2002CA2445763A1 Compositions comprising an anti-microtubule agent and a polypeptide or a polysaccharide and the use thereof for the preparation of a medicament for the treatment of inflammatory conditions
11/07/2002CA2445702A1 Control of compactability through crystallization
11/07/2002CA2445629A1 Substituted benzofurans and benzothiophenes, methods of making and methods of use as integrin antagonists
11/07/2002CA2445568A1 Triazole-derived kinase inhibitors and uses thereof
11/07/2002CA2445376A1 Substance rkb-3564 having angiogenesis inhibitory action
11/07/2002CA2445357A1 Pyrazole derived kinase inhibitors
11/07/2002CA2445348A1 Novel benzylpiperidine compound
11/07/2002CA2445338A1 G-protein coupled receptors
11/07/2002CA2445294A1 Bisarylimidazolyl fatty acid amide hydrolase inhibitors
11/07/2002CA2445290A1 A pharmaceutical tablet having a high api content
11/07/2002CA2444911A1 Fusion molecules and methods for treatment of immune diseases
11/07/2002CA2444882A1 Inhibitors of gsk-3 and crystal structures of gsk-3.beta. protein and protein complexes
11/07/2002CA2444500A1 Triazole compounds useful in treating diseases associated with unwanted cytokine activity
11/07/2002CA2444499A1 Triazole compounds useful in treating diseases associated with unwanted cytokine activity
11/07/2002CA2444436A1 Dual inhibitors of pde 7 and pde 4
11/07/2002CA2443835A1 Fused heterocyclic inhibitors of phosphodiesterase (pde) 7
11/07/2002CA2443381A1 Use of azithromycin for the manufacture of a medicament for treatment of non-infective inflammatory diseases
11/07/2002CA2439943A1 Benzimidazoles that are useful in treating sexual dysfunction
11/07/2002CA2429001A1 Cysteine protease inhibitors
11/07/2002CA2408369A1 Substituted indoles as parp inhibitors
11/06/2002EP1255112A2 Treatment of T-cell mediated diseases
11/06/2002EP1254902A1 Agents correcting gene expression regulatory error
11/06/2002EP1254899A2 Piperazine derivatives and their use as anti-inflammatory agents
11/06/2002EP1254898A1 Benzene-fused heterocycle derivatives and drugs containing the same as the active ingredient
11/06/2002EP1254897A1 Tricyclic compounds
11/06/2002EP1254667A1 Drug comprising combination
11/06/2002EP1254659A1 Stable emulsion compositions
11/06/2002EP1254270A1 Methods and materials relating to cub domain polypeptides and polynucleotides
11/06/2002EP1254268A1 Methods and materials relating to leucine-rich repeat protein-like (lrr protein-like) polypeptides and polynucleotides
11/06/2002EP1254264A1 Human protein tyrosine phosphatase polynucleotides, polypeptides, and antibodies
11/06/2002EP1254255A1 Trefoil domain-containing polynucleotides, polypeptides, and antibodies
11/06/2002EP1254246A1 Methods and materials relating to transforming growth factor alpha-like polypeptides and polynucleotides
11/06/2002EP1254239A2 Mammalian secreted group iii phospholipase a2
11/06/2002EP1254238A2 Novel elongase gene and method for producing multiple-unsaturated fatty acids
11/06/2002EP1254236A2 Drug metabolizing enzymes
11/06/2002EP1254235A2 Drug metabolizing enzymes
11/06/2002EP1254212A2 Methods of preparing and using a viral vector library
11/06/2002EP1254176A2 Trade molecules and uses related thereto
11/06/2002EP1254143A2 Lipid-based drug delivery systems
11/06/2002EP1254138A1 Pyridine derivatives inhibiting angiogenesis and/or vegf receptor tyrosine kinase
11/06/2002EP1254134A2 1,3-dihydro-2h-indol-2-one derivatives,and their use as ligands for v1b or v1b and v1a arginine-vasopressin-receptors
1 ... 893 894 895 896 897 898 899 900 901 902 903 904 905 906 907 908 909 910 911 912 913 ... 1272